Trial Profile
A phase III randomized study of humanized anti-IL-6 receptor antibody Tocilizumab (TCZ) to prevent development of acute graft versus host disease (GVHD) post Human Leuckocyte Antigen (HLA)-matched allogeneic haematopoietic progenitor cell transplantation (HPCT)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Feb 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Ciclosporin; Methotrexate
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 05 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 12 Jan 2021 Primary endpoint has not been met. (Incidence of grade II-IV (moderate to severe) acute GVHD will be assessed and graded according to the Seattle criteria.)
- 12 Jan 2021 Results published in the Blood